Skip to main content

The Wistar Institute

|

Novel Nanoparticle SARS-CoV-2 Vaccine Combines Immune Focusing and Self-assembling Nanoparticles to Elicit More Potent Protection

PHILADELPHIA — (Feb. 1, 2022) — The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants. Now scientists at…
Read more
|

The Wistar Institute Hosts U.S. Department of Commerce Official Making Major Grant Announcements to Strengthen Workforce Pipelines in Philadelphia & Across the Nation

Wistar is a finalist of the STEM Talent Challenge to create a new life science workforce training program to address Pennsylvania industry growth and demand for skilled workers. U.S. Assistant Secretary of Commerce for Economic Development Alejandra…
Read more
|

Wistar Scientists Identify Therapeutic Target for Epstein-Barr Virus

PHILADELPHIA — (Jan. 17, 2022) — A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, has identified a new potential pathway for developin…
Read more
|

The Wistar Institute Is Pleased to Announce the Promotion of Dr. Rahul Shinde to Assistant Professor, and the Promotions of Drs. Mohamed Abdel-Mohsen and Alessandro Gardini to Associate Professor

Wistar is honored these talented and accomplished scientists commit each day in their lab to bringing new and creative insights to cancer, immunology, and infectious disease research. Their original research makes them leaders in their fields and go…
Read more
|

Wistar and Stanford Medicine to Begin Phase 2 Clinical Trial of VK-2019 in Patients with Epstein-Barr Virus (EBV)-Positive Advanced Nasopharyngeal Carcinoma

PHILADELPHIA — (Jan. 5, 2022) — The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma. The study, led by researche…
Read more
|

Progress Toward a Cure: A Conversation with Leading Wistar HIV Research Scientist on World AIDS Day

On the eve of World AIDS Day, we chat with trailblazing scientist Dr. Luis Montaner, Herbert Kean, M.D., Family Professor, and leader of the HIV Research Program at Wistar. On Dec. 1, tune in to hear him in person as part of the NIH World AIDS Day 2…
Read more
|

Congratulations to Kylie Konrath the 2021 Monica H.M. Shander Memorial Fellowship Awardee

This prestigious award was established in 1981 in memory of former Wistar predoctoral trainee Monica H.M. Shander and is given annually to a predoctoral trainee who displays excellence in scholastics as well as aptitude and diligence in the laborato…
Read more
|

Fox Chase Cancer Center, The Wistar Institute Announce Opening of Phase 1 Clinical Trial of Anticancer Drug Candidate

PHILADELPHIA — (Dec. 2, 2021) — Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer. Gamitrinib is a first-in-class, mitochondrial-ta…
Read more
|

Wistar Scientists Identify Genes Critical to Protecting Ovarian Cancer from the Immune System

PHILADELPHIA — (Nov. 30, 2021) — Immunotherapies have shown striking clinical benefit in the treatment of many cancers, especially when used in combination with chemotherapy. However, some cancers respond poorly to immunotherapy, and ovarian cancer…
Read more
|

Wistar Study Identifies Two Genes That Protect Ovarian Cancer from the Immune System

Discovery could make immunotherapy more effective for ovarian and other cancers. Immunotherapy has shown significant benefits in treating many cancers, especially when combined with chemotherapy. But many cancers are resistant to immunotherapy. Ovar…
Read more